Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingrid L Titlestad

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
ERJ Open Research|April 27, 2019
Plasma microfibrillar-associated protein 4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patientsSofie Lock Johansson, Helle Wulf-Johansson, Anders Schlosser, et al.
Journal of Telemedicine and Telecare|November 15, 2013
The effect of real-time teleconsultations between hospital-based nurses and patients with severe COPD discharged after an exacerbationAnne Dichmann Sorknaes, Mickael Bech, Hanne Madsen, et al.
BMC Health Services Research|April 1, 2021
Prehospital emergency medical technicians can perform ultrasonography and blood analysis in prehospital evaluation of patients with chronic obstructive pulmonary disease: a feasibility studyGiti Nadim, Christian B Laursen, Pia I Pietersen, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|March 11, 2014
Surfactant protein D is a candidate biomarker for subclinical tobacco smoke-induced lung damageSofie L Johansson, Qihua Tan, René Holst, et al.
Respiratory Medicine|July 16, 2014
Microfibrillar-associated protein 4: a potential biomarker of chronic obstructive pulmonary diseaseSofie Lock Johansson, Nassim Bazeghi Roberts, Anders Schlosser, et al.
The Lancet. Respiratory Medicine|May 26, 2018
Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trialRichard J Russell, Latifa Chachi, J Mark FitzGerald, et al.
International Journal of Chronic Obstructive Pulmonary Disease|June 11, 2021
Exploring PI3Kδ Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled TrialsMalcolm Begg, J Nicole Hamblin, Emily Jarvis, et al.
The European Respiratory Journal|September 18, 2025
Two randomised controlled phase 2 studies of the oral neutrophil elastase inhibitor alvelestat in alpha-1 antitrypsin deficiencyJ Michael Wells, Ingrid L Titlestad, Hanan Tanash, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
ERJ Open Research|April 27, 2019
Plasma microfibrillar-associated protein 4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patientsSofie Lock Johansson, Helle Wulf-Johansson, Anders Schlosser, et al.
Journal of Telemedicine and Telecare|November 15, 2013
The effect of real-time teleconsultations between hospital-based nurses and patients with severe COPD discharged after an exacerbationAnne Dichmann Sorknaes, Mickael Bech, Hanne Madsen, et al.
BMC Health Services Research|April 1, 2021
Prehospital emergency medical technicians can perform ultrasonography and blood analysis in prehospital evaluation of patients with chronic obstructive pulmonary disease: a feasibility studyGiti Nadim, Christian B Laursen, Pia I Pietersen, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|March 11, 2014
Surfactant protein D is a candidate biomarker for subclinical tobacco smoke-induced lung damageSofie L Johansson, Qihua Tan, René Holst, et al.
Respiratory Medicine|July 16, 2014
Microfibrillar-associated protein 4: a potential biomarker of chronic obstructive pulmonary diseaseSofie Lock Johansson, Nassim Bazeghi Roberts, Anders Schlosser, et al.
The Lancet. Respiratory Medicine|May 26, 2018
Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trialRichard J Russell, Latifa Chachi, J Mark FitzGerald, et al.
International Journal of Chronic Obstructive Pulmonary Disease|June 11, 2021
Exploring PI3Kδ Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled TrialsMalcolm Begg, J Nicole Hamblin, Emily Jarvis, et al.
The European Respiratory Journal|September 18, 2025
Two randomised controlled phase 2 studies of the oral neutrophil elastase inhibitor alvelestat in alpha-1 antitrypsin deficiencyJ Michael Wells, Ingrid L Titlestad, Hanan Tanash, et al.
Pageof 2